💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Yttrium Chloride

CHEMBL5316164 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
195.3 g/mol
LogP
—
Phase
4

Yttrium chloride is an inorganic yttrium salt that serves primarily as a precursor and starting material for the synthesis of radioactive yttrium-90 labeled radiopharmaceuticals used in radioimmunotherapy and targeted radionuclide therapy of lymphomas and other cancers. The stable yttrium chloride can be used in research applications and as a pharmaceutical intermediate. In oncology, yttrium chemistry underpins radiolabeled antibody conjugates used for lymphoma treatment.

分子量

195.2600 g/mol

TPSA

0.00 Ų

治療領域

Lymphoma Leukemia

作用機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

SMILES

[Cl-].[Cl-].[Cl-].[Y+3]

InChI

InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3

Molecular Formula

Cl3Y

HBD / HBA

- / 3

回転可能結合数

0

重原子数

4

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Yttrium chloride is an inorganic yttrium salt that serves primarily as a precursor and starting material for the synthesis of radioactive yttrium-90 labeled radiopharmaceuticals used in radioimmunotherapy and targeted radionuclide therapy of lymphomas and other cancers. The stable yttrium chloride can be used in research applications and as a pharmaceutical intermediate. In oncology, yttrium chemistry underpins radiolabeled antibody conjugates used for lymphoma treatment.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Yttrium Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5316164. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10198055. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.